Who invested in Artios

One round we have observed, with the 8 investors named in it. Every figure came from a named source, and where the company reported a raise to the SEC itself, that is shown beside it.

BiotechHealthcare

Funding summaryUpdated 26 Oct 2026

$83Mraised across 1 round since 2018, from 1 source

Latest round: Series B, $83MAug 2018
Investors: 8

See who backed them

The rounds

Aug 2018
Series B$83M
- IP Group
- Novartis
- AbbVie
- Andera Partners
- M/VENTURES
- Arix Bioscience
- LSP/ Pfizer
- SV Health
Reported by FinSMEs

Founders and team

From Artios's own website: 21 on the team.

Michael T. AndriolePresident, Chief Executive Officer, and Director
Christine SilversteinChief Financial Officer
Graeme SmithChief Scientific Officer
Ian SmithChief Medical Officer
Jeremy B. FitchChief Business Officer
Roy WareChief Manufacturing and Technology Officer
Bryony HarropVP of Clinical Science
Caryn BarnettVP of Clinical Operations
Desiree HeadleyVP, Head of Clinical Science
Gillian LangfordVP of Translational Science
Guy C. RubleVP of Regulatory Affairs
Helen RobinsonVP of Biology
Pablo LeeVP of Medical Affairs
Robert HealdVP of Chemistry
Irena MelnikovaDirector
John HohnekerDirector
Michael A. AlrutzGeneral Counsel
Michelle DoigDirector

And 3 more on the team.

Everyone who backed them

IP GroupVC firm1round

NovartisVC firm1round

AbbVieCorporate VC1round

Andera PartnersPrivate equity1round

M/VENTURESVC firm1round

Arix BioscienceVC firm1round

LSP/ Pfizerno record of our own yet1round

SV Healthno record of our own yet1round

Missing a round, or an investor who was in one? Tell us.

Quick answers about Artios